Popular Filters
Trials for Atopic Dermatitis Patients
Monoclonal Antibodies
Lebrikizumab for Eczema
Recruiting2 awardsPhase 3
Anniston, Alabama
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
Topical Corticosteroid
Skin Barrier Cream + Fluticasone Propionate for Eczema
Recruiting1 awardPhase 2
Mountain View, California
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeram™ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Trials for AD Patients
Monoclonal Antibodies
Lebrikizumab for Eczema
Recruiting2 awardsPhase 3
Anniston, Alabama
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
Topical Corticosteroid
Skin Barrier Cream + Fluticasone Propionate for Eczema
Recruiting1 awardPhase 2
Mountain View, California
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeram™ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Phase 3 Trials
Monoclonal Antibodies
Lebrikizumab for Eczema
Recruiting2 awardsPhase 3
Anniston, Alabama
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Eczema
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.
Janus Kinase (JAK) Inhibitor
Abrocitinib for Atopic Dermatitis/Eczema
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.
Trials With No Placebo
Monoclonal Antibodies
Nemolizumab for Eczema
Recruiting1 awardPhase 2
Fountain Valley, California
This trial is testing nemolizumab, a medication designed to help children with moderate-to-severe eczema. Nemolizumab is a medication developed for treating skin diseases, including severe eczema. The drug works by blocking proteins that cause skin problems and itching. Researchers aim to see how well it works and if it is safe for these children.
Monoclonal Antibodies
Lebrikizumab for Eczema
Recruiting2 awardsPhase 3
Anniston, Alabama
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.
Topical Corticosteroid
Skin Barrier Cream + Fluticasone Propionate for Eczema
Recruiting1 awardPhase 2
Mountain View, California
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeram™ has been previously tested for preventing eczema in infants with a family history of allergic disease.
Monoclonal Antibodies
Dupilumab for Eczema
Recruiting3 awardsPhase 3
Birmingham, Alabama
This trial is testing the long-term safety and efficacy of dupilumab, a medication used to treat eczema, in children. The trial will also assess the levels of functional dupilumab in the blood after repeated treatment and the immunogenicity of the medication.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.